Robert Negrin

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. pmc A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model
    Carina A Bäuerlein
    Department of Medicine II, Würzburg University Clinics, Zinklesweg 10, Wurzburg, D 97078, Germany
    BMC Med 11:134. 2013
  2. pmc Role of regulatory T cell populations in controlling graft vs host disease
    Robert S Negrin
    Center for Clinical Sciences, 269 W Campus Drive, Stanford University, Stanford, CA 94305, USA
    Best Pract Res Clin Haematol 24:453-7. 2011
  3. ncbi request reprint In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease
    Robert S Negrin
    Department of Medicine, Center for Clinical Research Building, 269 West Campus Drive, Stanford University, Stanford, California 94305, USA
    Nat Rev Immunol 6:484-90. 2006
  4. ncbi request reprint Methods for imaging cell fates in hematopoiesis
    Jennifer Duda
    Program in Molecular Imaging at Stanford, Stanford University School of Medicine, Stanford, CA, USA
    Methods Mol Med 134:17-34. 2007
  5. ncbi request reprint In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation
    Vu H Nguyen
    Department of Medicine, Division of Bone Marrow Transplantation, Stanford University, Stanford, CA 94305, USA
    Blood 109:2649-56. 2007
  6. ncbi request reprint Role of naturally arising regulatory T cells in hematopoietic cell transplantation
    Vu H Nguyen
    Center for Clinical Science Research, Department of Medicine, Division of Bone Marrow Transplantation, Stanford University, Stanford, CA 94305, USA
    Biol Blood Marrow Transplant 12:995-1009. 2006
  7. pmc The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia
    Vivian G Oehler
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 109:1782-9. 2007
  8. ncbi request reprint High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma
    Lisa Y Law
    Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 12:703-11. 2006
  9. ncbi request reprint Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Cancer Center, Stanford University, Stanford, California, USA
    Clin Cancer Res 12:1859-67. 2006
  10. pmc Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease
    Robert Zeiser
    Division of Bone Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, CA 94305, USA
    Blood 109:2225-33. 2007

Research Grants

  1. NK Cells in GVHD and GVT
    Robert S Negrin; Fiscal Year: 2010
  2. Training Program in Hematopoietic Cell Transplantation
    Robert Negrin; Fiscal Year: 2007
  3. BONE MARROW GRAFTING FOR LEUKEMIA AND LYMPHOMA
    Robert Negrin; Fiscal Year: 2007
  4. VISUALIZING TUMORS AND MECHANISMS OF THERAPY IN VIVO
    Robert Negrin; Fiscal Year: 2007
  5. VISUALIZING TUMORS AND MECHANISMS OF THERAPY IN VIVO
    Robert Negrin; Fiscal Year: 2002

Collaborators

Detail Information

Publications48

  1. pmc A diagnostic window for the treatment of acute graft-versus-host disease prior to visible clinical symptoms in a murine model
    Carina A Bäuerlein
    Department of Medicine II, Würzburg University Clinics, Zinklesweg 10, Wurzburg, D 97078, Germany
    BMC Med 11:134. 2013
    ..Here we address whether insights into the timing of the aGVHD initiation and effector phases could allow for the detection of migrating alloreactive T cells before clinical aGVHD onset to permit for efficient therapeutic intervention...
  2. pmc Role of regulatory T cell populations in controlling graft vs host disease
    Robert S Negrin
    Center for Clinical Sciences, 269 W Campus Drive, Stanford University, Stanford, CA 94305, USA
    Best Pract Res Clin Haematol 24:453-7. 2011
    ..This manuscript will focus on CD4+CD25+FoxP3+ natural regulatory T cells (T(reg)) and αβTCR+CD4+NK1.1+ natural killer T (NK-T) cells which both suppress graft vs host disease but appear to function by distinct mechanisms...
  3. ncbi request reprint In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease
    Robert S Negrin
    Department of Medicine, Center for Clinical Research Building, 269 West Campus Drive, Stanford University, Stanford, California 94305, USA
    Nat Rev Immunol 6:484-90. 2006
    ..This strategy could be useful for the study of a wide range of biological processes, such as the pathophysiology of graft-versus-host and graft-versus-leukaemia reactions...
  4. ncbi request reprint Methods for imaging cell fates in hematopoiesis
    Jennifer Duda
    Program in Molecular Imaging at Stanford, Stanford University School of Medicine, Stanford, CA, USA
    Methods Mol Med 134:17-34. 2007
    ..The goal of this chapter is to provide adequate background information to allow the design and implementation of an experimental system for in vivo imaging in mice...
  5. ncbi request reprint In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation
    Vu H Nguyen
    Department of Medicine, Division of Bone Marrow Transplantation, Stanford University, Stanford, CA 94305, USA
    Blood 109:2649-56. 2007
    ....
  6. ncbi request reprint Role of naturally arising regulatory T cells in hematopoietic cell transplantation
    Vu H Nguyen
    Center for Clinical Science Research, Department of Medicine, Division of Bone Marrow Transplantation, Stanford University, Stanford, CA 94305, USA
    Biol Blood Marrow Transplant 12:995-1009. 2006
    ..In this review, we discuss the current knowledge of Treg biology and the potential therapeutic strategies and barriers of Treg immunotherapy in human hematopoietic cell transplantation...
  7. pmc The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia
    Vivian G Oehler
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 109:1782-9. 2007
    ..However, patients with a suboptimal or loss of IM response before HCT do worse, suggesting a more aggressive disease course for these patients...
  8. ncbi request reprint High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma
    Lisa Y Law
    Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 12:703-11. 2006
    ..Patients who had required >3 previous chemotherapy regimens before HCT had an increased probability of relapse. CBV is an effective preparative regimen for patients with aggressive NHL who undergo allogeneic HCT...
  9. ncbi request reprint Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Cancer Center, Stanford University, Stanford, California, USA
    Clin Cancer Res 12:1859-67. 2006
    ..Bispecific antibodies significantly enhanced the cytotoxicity of CIK cells in primary ovarian cancer cells and in our in vivo mouse model. The mechanism of cytolysis seems to be mediated in part by the NKG2D receptor...
  10. pmc Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease
    Robert Zeiser
    Division of Bone Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, CA 94305, USA
    Blood 109:2225-33. 2007
    ..These data demonstrate that early CD30 signaling is critical for Treg-mediated aGvHD protection after major MHC-mismatch bone marrow transplantation...
  11. ncbi request reprint CD101 surface expression discriminates potency among murine FoxP3+ regulatory T cells
    Irina Fernandez
    Departamento de Biologia Celular, Universidad Simon Bolivar, Caracas, Venezuela corrected
    J Immunol 179:2808-14. 2007
    ..Among the CD101(high) Treg all of the in vivo suppressor activity was contained within the CD62L(high) subpopulation. We conclude that CD101 expression distinguishes murine Treg with potent suppressor activity...
  12. pmc Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity
    Robert Zeiser
    Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    Blood 110:4588-98. 2007
    ....
  13. pmc The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation
    Vu H Nguyen
    Department of Medicine, Stanford University, CA, USA
    Blood 111:945-53. 2008
    ..These findings provide new insights into the role of Tregs in affording protection to lymphoid stromal elements important for T-cell immunity...
  14. pmc Plasmacytoid dendritic cells take up opsonized antigen leading to CD4+ and CD8+ T cell activation in vivo
    Pia Björck
    Department of Pathology Stanford Blood Center, Division of Blood and Marrow Transplantation, Stanford University, Palo Alto, CA 94304, USA
    J Immunol 181:3811-7. 2008
    ..These results indicate that pDC can shape an immune response by acquiring and processing opsonized Ag, leading to a predominantly Th2 response...
  15. pmc In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity
    Ryosei Nishimura
    Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University, CA 94305, USA
    Blood 112:2563-74. 2008
    ..Due to these properties, allogeneic CIK cells had reduced expansion and caused less tissue damage. We conclude that CIK cells have the potential to separate graft-versus-tumor effects from GVHD...
  16. pmc Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience
    Andy I Chen
    Stanford University Medical Center, Division of Blood and Marrow Transplantation, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 14:741-7. 2008
    ....
  17. pmc Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen
    Ginna G Laport
    Division of Blood and Marrow Transplantation, Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305 5623, USA
    Blood 112:903-9. 2008
    ..Our results indicate that FTBI/VP16 with or without cyclophosphamide confers long-term survival in Ph(+) ALL patients and that disease status at the time of HCT is an important predictor of outcome...
  18. ncbi request reprint Acute graft-versus-host disease-challenge for a broader application of allogeneic hematopoietic cell transplantation
    Robert Zeiser
    Division of Bone Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, California 94305, USA
    Curr Stem Cell Res Ther 1:203-12. 2006
    ..A better understanding of the mechanisms involved in aGVHD pathogenesis might allow for a broader application of novel stem cell therapies...
  19. pmc Host-derived interleukin-18 differentially impacts regulatory and conventional T cell expansion during acute graft-versus-host disease
    Robert Zeiser
    Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 13:1427-38. 2007
    ..We conclude that host-derived IL-18 is a major factor for IFN-gamma production that may have a protective effect on CD4(+)-mediated aGVHD, but is nonessential for Treg expansion in an allogeneic environment...
  20. pmc Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs
    Andreas Beilhack
    Department of Medicine, Stanford University, 269 W Campus Drive, Stanford, CA 94305, USA
    Blood 111:2919-28. 2008
    ..Thus, we demonstrate redundancy of SLOs at different anatomical sites in aGVHD initiation. Only prevention of T-cell entry to all SLOs could completely abrogate the onset of aGVHD...
  21. pmc Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells
    Robert Zeiser
    Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    Blood 111:453-62. 2008
    ....
  22. ncbi request reprint Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells
    Mobin Karimi
    Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Immunol 175:7819-28. 2005
    ..These studies demonstrated the importance of NKG2D, DAP10, and DAP12 in human effector cell function...
  23. pmc Ex vivo expanded dendritic cells home to T-cell zones of lymphoid organs and survive in vivo after allogeneic bone marrow transplantation
    Christoph H Schimmelpfennig
    Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Center for Clinical Science Building, Room 2205, 269 West Campus Dr, Stanford, CA 94305, USA
    Am J Pathol 167:1321-31. 2005
    ..These findings are important for adoptive immunotherapies because they indicate that eDCs migrate efficiently in vivo and are capable of surviving long term...
  24. ncbi request reprint Protective conditioning for acute graft-versus-host disease
    Robert Lowsky
    Department of Medicine, Stanford University School of Medicine, Stanford, Calif, USA
    N Engl J Med 353:1321-31. 2005
    ..Conditioning with total lymphoid irradiation plus antithymocyte serum protects mice against acute graft-versus-host disease (GVHD) after hematopoietic-cell transplantation. We tested this strategy in humans...
  25. ncbi request reprint Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3
    Christian Scheffold
    Division of Bone Marrow Transplantation, Stanford University School of Medicine, California 94305, USA
    Cancer Res 62:5785-91. 2002
    ..These studies have demonstrated that CD8+ NKT cells can be successfully redirected to tumor cells using bispecific antibodies and offer a promising strategy for adoptive immunotherapy of neoplastic diseases...
  26. ncbi request reprint Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation
    Heather G Shilling
    Department of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Blood 101:3730-40. 2003
    ..These results demonstrate that a majority of HLA-matched hematopoietic cell transplantations involve KIR mismatch and reveal differences in NK cell repertoire having potential impact for immune responsiveness and transplantation outcome...
  27. ncbi request reprint Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma
    Steven M Horwitz
    Division of Oncology, Stanford University Medical Center, Ste 202, 1000 Welch Rd, Palo Alto, CA 94304, USA
    Blood 103:777-83. 2004
    ..Rituximab after HDT and HCT is feasible, and these phase 2 data support the current US Intergroup phase 3 trial in recurrent/refractory diffuse large cell lymphoma...
  28. ncbi request reprint CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation
    Matthias Edinger
    Division of Bone Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, California 94305, USA
    Nat Med 9:1144-50. 2003
    ..Thus, CD4+CD25+ T cells are potent regulatory cells that can separate GVHD from GVT activity mediated by conventional donor T cells...
  29. pmc Shifting foci of hematopoiesis during reconstitution from single stem cells
    Yu An Cao
    Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 101:221-6. 2004
    ....
  30. ncbi request reprint Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD
    Joerg Ermann
    Division of Immunology and Rheumatology, The Department of Medicine, Stanford University School of Medicine, CCSR Bldg, Rm 2215 C, 300 Pasteur Dr, Stanford, CA 94305 5166, USA
    Blood 105:2220-6. 2005
    ..The ability of Treg cells to efficiently enter the priming sites of pathogenic allo-reactive T cells appears to be a prerequisite for their protective function in aGVHD...
  31. ncbi request reprint Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose
    Thai M Cao
    Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University Schol of Medicine, 300 Pasteur Dr, H3249, MC 5623, Stanford, CA 94305 5623, USA
    Blood 105:2300-6. 2005
    ..003; RR = 0.2, 95% CI = 0.1-0.6) was associated with improved freedom from progression. Infusion of low G-PBMC CD8+ T-cell dose for reduced-intensity allografting may adversely affect T-cell engraftment and survival outcome...
  32. ncbi request reprint Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease
    Laura J Johnston
    Stanford University, Stanford, California 94305, USA
    Biol Blood Marrow Transplant 11:47-55. 2005
    ..Given the significant toxicities described, investigation of altered administration of rapamycin and calcineurin inhibitors should be pursued in future cGVHD trials...
  33. ncbi request reprint Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system
    Judith A Shizuru
    Division of Blood and Marrow Transplantation, Stanford University Medical Center, California 94305, USA
    Annu Rev Med 56:509-38. 2005
    ....
  34. ncbi request reprint Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia
    Vivian G Oehler
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Biol Blood Marrow Transplant 11:85-92. 2005
    ..10) and a higher cumulative incidence of chronic GVHD in PBSC recipients (59% versus 40%; P = .11). The trend toward a higher relapse incidence in BM recipients persisted with a longer follow-up...
  35. ncbi request reprint Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation
    Yu An Cao
    Department of Pediatrics, Stanford School of Medicine, Stanford, California, USA
    Transplantation 80:134-9. 2005
    ..This imaging approach is sensitive and reproducible, permits study of the dynamic range of the entire process of transplantation, and will greatly enhance studies across various disciplines involving transplantation...
  36. ncbi request reprint Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells
    Michael R Verneris
    Department of Pediatrics, Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Clin Cancer Res 11:4561-70. 2005
    ..To identify novel treatments for pediatric solid tumors and/or for malignancies with low-level Her2/neu expression...
  37. pmc In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets
    Andreas Beilhack
    Department of Medicine, Stanford University, Stanford, CA 94305, USA
    Blood 106:1113-22. 2005
    ..These findings underline the potential of T-cell subsets with defined trafficking patterns for immune reconstitution without the risk of GVHD...
  38. ncbi request reprint Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice
    Michael R Verneris
    Division of Pediatric Hematology Oncology, and Bone Marrow Transplantation, Stanford, California 94305, USA
    J Clin Immunol 22:131-6. 2002
    ..We conclude that expanded CD8+ NK-T cells are a promising form of cellular therapy in the allogeneic setting...
  39. ncbi request reprint A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma
    Thomas Leemhuis
    Division of Bone Marrow Transplantation, Stanford University Medical Center, California, USA
    Biol Blood Marrow Transplant 11:181-7. 2005
    ....
  40. ncbi request reprint CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies
    Thai M Cao
    Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5623, USA
    Exp Hematol 33:279-85. 2005
    ..G-PBMC cell contents were analyzed for influence on outcomes...
  41. ncbi request reprint Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells
    Michael R Verneris
    Division of Pediatric Blood and Marrow Diseases, University of Minnesota, Minneapolis, MN 55455, USA
    Blood 103:3065-72. 2004
    ..Collectively these results establish that NKG2D triggering accounts for the majority of major histocompatibility complex (MHC)-unrestricted cytotoxicity of activated and expanded CD8+ T cells, likely through DAP10-mediated signaling...
  42. ncbi request reprint Immune regulatory networks in the post-transplant setting
    Robert S Negrin
    Blood Cells Mol Dis 40:117-8. 2008
  43. ncbi request reprint Multi-modality imaging identifies key times for annexin V imaging as an early predictor of therapeutic outcome
    Stefanie J Mandl
    Stanford University, School of Medicine, CA 94305 5208, USA
    Mol Imaging 3:1-8. 2004
    ..Multimodality imaging revealed the temporal patterns of tumor cell loss and annexin V uptake revealing a better understanding of the timing of radiolabeled annexin V uptake for its development as a marker of therapeutic efficacy...
  44. ncbi request reprint Synergistic antitumor effects of immune cell-viral biotherapy
    Steve H Thorne
    Departments of Pediatrics, Radiology, Microbiology, and Immunology Stanford University School of Medicine, Stanford, CA 94305, USA
    Science 311:1780-4. 2006
    ..These results illustrate the potential of combining biotherapeutics for synergistic effects that more effectively treat cancer...
  45. ncbi request reprint Understanding immune cell trafficking patterns via in vivo bioluminescence imaging
    Stefanie Mandl
    Department of Pediatrics, Stanford University, Stanford, California 94305, USA
    J Cell Biochem Suppl 39:239-48. 2002
    ..Such rapid assays that reveal cell fates in vivo will increase our basic understanding of the molecular signals that control these migratory pathways and will substantially speed up the development and evaluation of therapies...
  46. ncbi request reprint Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging
    Matthias Edinger
    Division of Bone Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, CA, USA
    Blood 101:640-8. 2003
    ..The complex cellular processes in bone marrow transplantation and antitumor immunotherapy, previously inaccessible to investigation, can now be revealed in real time in living animals...
  47. pmc Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production
    Robert Zeiser
    Center for Clinical Science Research, Division of Bone Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    Blood 108:390-9. 2006
    ..Our data indicate that RAPA and MMF rather than CSA preserve function of Treg cells in pathologic immune responses such as GVHD without weakening the GVT effect...
  48. ncbi request reprint Evaluation of effector cell fate and function by in vivo bioluminescence imaging
    Matthias Edinger
    Department of Hematology and Oncology, University of Regensburg, 93042 Regensburg, Germany
    Methods 31:172-9. 2003
    ..Here, we highlight one of the newer modalities, in vivo bioluminescence imaging, as a method for evaluating effector T cell proliferation, migration, and function in model systems of malignant and non-malignant diseases...

Research Grants16

  1. NK Cells in GVHD and GVT
    Robert S Negrin; Fiscal Year: 2010
    ..tumor effects without graft vs host disease using novel bioluminescent based imaging strategies to explore the temporal and spatial events in natural killer cell biology in models of these events. ..
  2. Training Program in Hematopoietic Cell Transplantation
    Robert Negrin; Fiscal Year: 2007
    ..At the conclusion of their training, individuals will be prepared for a career as an independent investigator well studied in the basic and clinical areas of hematopoietic cell transplantation. (End of Abstract) ..
  3. BONE MARROW GRAFTING FOR LEUKEMIA AND LYMPHOMA
    Robert Negrin; Fiscal Year: 2007
    ..As a whole this integrated group of investigators will focus their efforts on critical issues of hematopoietic cell transplantation and cellular based therapeutics. ..
  4. VISUALIZING TUMORS AND MECHANISMS OF THERAPY IN VIVO
    Robert Negrin; Fiscal Year: 2007
    ..These insights will be utilized to develop strategies translatable to the clinic to improve outcomes for patients with a broad range of malignant conditions. ..
  5. VISUALIZING TUMORS AND MECHANISMS OF THERAPY IN VIVO
    Robert Negrin; Fiscal Year: 2002
    ..Elucidating the mechanism by which tumor cells are killed by immune cells and maximizing this effect in vivo will greatly enhance our ability to apply these cell therapies to the control of human malignant disease. ..